Intelligence · Clinical Development
Pipeline search results
Programs matching “venetoclax” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 33 pipeline programs matching "venetoclax" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Azacitidine Combined With Venetoclax and ATRA group
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
Experimental: Venetoclax in combination with Decitabine (+-sorafenib)
Kunming Hope of Health Hospital
Elderly AML Patients
1 trial -
Intermediate-dose Cytarabine in Combination with Venetoclax
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia (AML)
1 trial -
Venetoclax
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Lymphoblastic Leukemia
1 trial -
Venetoclax
Xiyuan Hospital of China Academy of Chinese Medical Sciences
AML
2 trials -
Venetoclax
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
Venetoclax
AbbVie
Chronic Lymphocytic Leukemia
1 trial -
Venetoclax 400
United Therapeutics Europe Ltd
Acute Myeloid Leukemia
1 trial -
Venetoclax in combination with fludarabine and melphalan
The First People's Hospital of Lianyungang
Venentoclax
1 trial -
venetoclax
The First People's Hospital of Lianyungang
Acute Promyelocytic Leukemia
1 trial -
Azacitidine in Combination With Venetoclax
The First People's Hospital of Lianyungang
Hematologic Malignancy
1 trial -
IIT2024067
Xiyuan Hospital of China Academy of Chinese Medical Sciences
AML
1 trial -
IIT2024097
Xiyuan Hospital of China Academy of Chinese Medical Sciences
AML (Acute Myelogenous Leukemia)
1 trial -
Ivosidenib combined with venetoclax and azacitidine
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
VEN (Venetoclax)
The First People's Hospital of Lianyungang
Myelodysplastic Neoplasms
1 trial -
VEN (Venetoclax)
The First People's Hospital of Lianyungang
Adult T-cell Leukemia/Lymphoma
1 trial -
Venetoclax
The First People's Hospital of Lianyungang
Precursor B-Cell Acute Lymphoblastic Leukemia
1 trial -
Venetoclax
Syndax Pharmaceuticals
Acute Myeloid Leukemia
1 trial -
Venetoclax
TG THERAPEUTICS, INC.
Chronic Lymphocytic Leukemia
1 trial -
Venetoclax
The First People's Hospital of Lianyungang
Acute Leukemia of Ambiguous Lineage
1 trial -
Venetoclax
Xiyuan Hospital of China Academy of Chinese Medical Sciences
FLT3 Gene Mutation
1 trial -
Venetoclax
The First People's Hospital of Lianyungang
Early T Acute Lymphoblastic Leukemia
1 trial -
Venetoclax monotherapy
Adaptive Biotechnologies Corp
Chronic Lymphocytic Leukemia (CLL)
1 trial -
Venetoclax, Azacitidine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Myeloid Leukemia
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.